Publicacions

Francesc Artigas

Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder

Artigas F, Bortolozzi A ,

2016

Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex.

Riga MS, Teruel-Martí V, Sanchez C, Celada P, Artigas F,

2016

Glucocorticoid receptors, brain-derived neurotrophic factor, serotonin and dopamine neurotransmission are associated with interferon-induced depression

Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D, Valdés M, Gómez-Gil E, Grande I, Gratacós M, Kapczinski F, Artigas F, Vieta E, Solà R, Martín-Santos R,

2016

A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment.

Nilsson S, Celada P, Fejgin K, Thelin J, Nielsen J, Santana N, Heath C, Larsen P, Nielsen V, Kent B, Robbins T, Saksida L, Stensbøl T, Bastlund J, Bussey T, Artigas F, Didriksen M ,

2016

Behavioral traits propagate across generations via segregated iterative-somatic and gametic epigenetic mechanisms

Mitchell E, Klein S, Argyropoulos KV, Sharma A, Chan RB, Toth JG, Barboza L, Bavley C, Bortolozzi A, Chen Q, Liu B, Ingenito J, Mark W, Dudakov J, Gross S, Di Paolo G, Artigas F, van den Brink M, Toth M ,

2016

Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission

Riga MS, Sánchez C, Celada P, Artigas F,

2016

Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: Effects of antipsychotic drugs and receptor ligands

Lladó-Pelfort L, Troyano-Rodriguez E, Van den Munkhof HE, Cervera-Ferri A, Jurado N, Núñez-Calvet M, Artigas F, Celada P ,

2016

Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration

Ferrés-Coy A, Galofré M, Pilar-Cuéllar F, Vidal R, Paz V, Ruiz-Bronchal E, Campa L, Pazos A, Caso JR, Leza JC, Alvarado G, Montefeltro A, Valdizán EM, Artigas F, Bortolozzi A,

2016

The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors

Riga MS, Bortolozzi A, Campa L, Artigas F, Celada P,

2016

''DEVELOPMENTS IN THE FIELD OF ANTIDEPRESSANTS, WHERE DO WE GO NOW?''

ARTIGAS F,

2015

''5-HT2A RECEPTORS ARE INVOLVED IN COGNITIVE BUT NOT ANTIDEPRESSANT EFFECTS OF FLUOXETINE.''

CASTAÑÉ A, KARGIEMAN L, CELADA P, BORTOLOZZI A, ARTIGAS F.,

2015

''THERAPEUTIC ANTIDEPRESSANT POTENTIAL OF A CONJUGATED SIRNA SILENCING THE SEROTONIN TRANSPORTER AFTER INTRANASAL ADMINISTRATION.''

FERRÉS-COY A, GALOFRÉ M, PILAR-CUÉLLAR F, VIDAL R, PAZ V, RUIZ-BRONCHAL E, CAMPA L, PAZOS Á, CASO JR, LEZA JC, ALVARADO G, MONTEFELTRO A, VALDIZÁN EM, ARTIGAS F, BORTOLOZZI A.,

2015

''VORTIOXETINE, A NOVEL ANTIDEPRESSANT WITH MULTIMODAL ACTIVITY: REVIEW OF PRECLINICAL AND CLINICAL DATA.''

SANCHEZ C, ASIN KE, ARTIGAS F.,

2015

''EXPRESSION OF 5-HT2A RECEPTORS IN PREFRONTAL CORTEX PYRAMIDAL NEURONS PROJECTING TO NUCLEUS ACCUMBENS. POTENTIAL RELEVANCE FOR ATYPICAL ANTIPSYCHOTIC ACTION.''

MOCCI G, JIMÉNEZ-SÁNCHEZ L, ADELL A, CORTÉS R, ARTIGAS F.,

2014

''RNAI-MEDIATED SEROTONIN TRANSPORTER SUPPRESSION RAPIDLY INCREASES SEROTONERGIC NEUROTRANSMISSION AND HIPPOCAMPAL NEUROGENESIS. ''

FERRES-COY A, PILAR-CUELLAR F, VIDAL R, PAZ V, MASANA M, CORTES R, CARMONA MC, CAMPA L, PAZOS A, MONTEFELTRO A, VALDIZAN EM, ARTIGAS F, BORTOLOZZI A,

2013

''SEROTONIN MODULATION OF CORTICAL NEURONS AND NETWORKS.''

CELADA P, PUIG MV, ARTIGAS F.,